Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX

PURPOSE: The benefit of adjuvant chemotherapy following curative-intent surgery in pancreatic ductal adenocarcinoma (PDAC) patients who had received neoadjuvant FOLFIRINOX is unclear. This study aimed to assess the survival benefit of adjuvant chemotherapy in this patient population. MATERIALS AND M...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, So Heun, Hwang, Dae Wook, Yoo, Changhoon, Kim, Kyu-pyo, Kang, Sora, Jeong, Jae Ho, Oh, Dongwook, Song, Tae Jun, Lee, Sang Soo, Park, Do Hyun, Seo, Dong Wan, Park, Jin-hong, Song, Ki Byung, Lee, Jae Hoon, Lee, Woohyung, Park, Yejong, Kwak, Bong Jun, Chang, Heung-Moon, Ryoo, Baek-Yeol, Kim, Song Cheol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372602/
https://www.ncbi.nlm.nih.gov/pubmed/36915253
http://dx.doi.org/10.4143/crt.2022.409

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372602/
https://www.ncbi.nlm.nih.gov/pubmed/36915253
http://dx.doi.org/10.4143/crt.2022.409

Ejemplares similares